BRAF抑制剂联合MEK抑制剂相关发热综合征的医-药-患共管模式专家共识  

Experts Consensus on Physician-Pharmacist-Patient Co-Management Mode on BRAF Inhibitor plus MEK Inhibitor Combination Therapy Related Pyrexia Syndrome

作　　者：黄硕涵 尹月 黄萍 谢瑞祥[5] 刘玉国 方罗[7] 孙言才 魏继福[9] 刘丽娟[10] 黄红兵[11] 董梅[12] 李国辉[13] 张艳华 翟青 杜琼[1,2] HUANG Shuo-han;YIN Yue;HUANG Ping;XIE Rui-xiang;LIU Yu-guo;FANG Luo;SUN Yan-cai;WEI Ji-fu;LIU Li-juan;HUANG Hong-bing;DONG Mei;LI Guo-hui;ZHANG Yan-hua;ZHAI Qing;DU Qiong(Department of Pharmacy,Fudan University Shanghai Cancer Center,Shanghai 200032,China;Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China;Department of Pharmacy,Peking University Cancer Hospital and Institute,Beijing 100142,China;Department of Pharmacy,Zhejiang Provincial People′s Hospital,People′s Hospital of Hangzhou Medical College,Hangzhou 310010,China;Department of Pharmacy,Fujian Provincial Cancer Hospital,Fuzhou 350014,China;Department of Pharmacy,Shandong Institute of Cancer Prevention and Treatment(Shandong Cancer Hospital),Jinan 250117,China;Department of Pharmacy,Zhejiang Cancer Hospital,Hangzhou 310022,China;Department of Pharmacy,Anhui Provincial Cancer Hospital,Hefei 230031,China;Department of Pharmacy,Affiliated Cancer Hospital of Nanjing Medical University(Jiangsu Cancer Hospital),Nanjing 210009,China;Department of Pharmacy,Jiangxi Cancer Hospital,Nanchang 330029,China;Department of Pharmacy,Sun Yat-sen University,Cancer Center,Guangzhou 510060,China;Department of Pharmacy,Harbin Medical University Cancer Hospital,Harbin 150086,China;Department of Pharmacy,Cancer Hospital Chinese Academy of Medical Sciences,Beijing 100029,China)

机构地区：[1]复旦大学附属肿瘤医院药剂科,上海200032 [2]复旦大学上海医学院肿瘤学系,上海200032 [3]北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科,北京100142 [4]浙江省人民医院药剂科,杭州医学院附属人民医院,杭州310010 [5]福建省肿瘤医院药剂科,福州350014 [6]山东省肿瘤防治研究院(山东省肿瘤医院)药剂科,济南250117 [7]浙江省肿瘤医院药剂科,杭州310022 [8]安徽省肿瘤医院药剂科,合肥230031 [9]南京医科大学附属肿瘤医院(江苏省肿瘤医院)药学部,南京210009 [10]江西省肿瘤医院药剂科,南昌330029 [11]中山大学肿瘤防治中心药剂科,广州510060 [12]哈尔滨医科大学附属肿瘤医院药学部,哈尔滨150086 [13]中国医学科学院肿瘤医院药剂科,北京100029

出　　处：《中国药学杂志》2023年第16期1524-1530,共7页Chinese Pharmaceutical Journal

基　　金：上海市抗癌协会“翱翔”计划资助(SACA-AX202110)。

摘　　要：发热综合征是鼠类肉瘤病毒癌基因同源物B1(v-raf murine sarcoma viral oncogene homolog B1,BRAF)抑制剂(BRAF inhibitor,BRAFi)联合丝裂原细胞外激酶(mitogen-activated extracellular signal-regulated kinase,MEK)抑制剂(MEK inhibitor,MEKi)的联合治疗治疗中常见的不良反应,机制尚不明.

关 键 词：鼠类肉瘤病毒癌基因同源物B1抑制剂 丝裂原细胞外激酶抑制剂 发热综合征 医-药-患共管模式 

分 类 号：R979.1[医药卫生—药品]